分类1

Schizophrenia Animal Model

分类：

Model Introduction

Schizophrenia is a complex and severe mental illness that usually has a slow or subacute onset. It typically involves functional impairments in cognition, behavior, and emotion, with highly heterogeneous clinical manifestations. Symptoms are primarily divided into three categories:

  • Positive symptoms: Including hallucinations, delusions, conceptual disorganization, and thought form disorders;
  • Negative symptoms: Including blunted affect, anhedonia, social withdrawal, avolition, and stereotyped thinking;
  • Cognitive impairment: Involving deficits in learning, memory, and executive function.

Animal models simulate the pathological changes and phenotypic characteristics of schizophrenia, providing an experimental basis for exploring its pathogenesis and intervention strategies. Current rodent models of schizophrenia mainly include:

  1. Pharmacological models
  2. Neurodevelopmental models
  3. Transgenic models
  4. Comprehensive multi-method models

Among these, pharmacological models are the most widely used and classic, while neurodevelopmental and transgenic models more closely resemble the onset process of human schizophrenia and have gradually become research hotspots in recent years.

Research Applications

Schizophrenia animal models can be used to:

  • Simulate positive, negative, and cognitive impairment symptoms;
  • Analyze abnormalities in neurotransmitter systems (e.g., NMDA receptor dysfunction);
  • Study the interaction between neurodevelopmental abnormalities and environmental factors;
  • Explore the relationship between susceptibility genes and behavioral phenotypes;
  • Evaluate the mechanism of action of antipsychotic drugs.

Comprehensive models, because they can integrate multiple pathogenic factors, are closer to the complex etiological structure of schizophrenia and represent an important direction for ideal model construction in the future.

Key Points of Experimental Design

I. Pharmacological Animal Models

  1. PCP-Induced Model
    • PCP is a non-competitive NMDA receptor antagonist that induces positive and negative symptoms.
    • SD rats: 7.5 mg/kg, i.p., once daily for 14 consecutive days.
    • DDY male mice: 3 mg/kg or 10 mg/kg, subcutaneous (s.c.) injection for 2 weeks.
    • This model induces reduced social behavior and is used to study negative symptoms.
  2. Ketamine-Induced Model
    • Chronic administration model: 5-week-old SD rats, 15/30/60 mg/kg i.p., twice daily for 1 week.
    • Repeated neonatal treatment model: Starting from postnatal day 6, 15/30/60 mg/kg s.c., twice daily until day 21.
    • Characteristics: Leads to persistent working memory deficits in adulthood with minimal effect on spontaneous activity, suitable for cognitive impairment research.
  3. MK801-Induced Model
    • MK801 is a non-competitive NMDA receptor antagonist.
    • BALB/c, C57BL/6, and ICR mice can be modeled with 0.6 mg/kg i.p.
    • Advantages: Stable and reproducible; exhibits hyperlocomotion and stereotyped behavior.
    • Limitations: Results are influenced by dose and administration route.
  4. CPZ-Induced Model
    • C57BL/6 mice fed with 0.2% CPZ.
    • Advantages: Exhibits white matter demyelination and psychosis-like symptoms.

II. Neurodevelopmental Models

  1. Early Hippocampal Lesion Model
    • Injection of IBO into the ventral hippocampus of 7-day-old rats.
    • Characteristics: Symptoms appear after puberty, aligning with the human onset timeline.
  2. Isolation Rearing Model
    • Single-cage housing of male SD rats after weaning.
    • Characteristics: Increased body mass, decreased environmental adaptability.
    • Limitations: Minor environmental differences can significantly affect results.
  3. Maternal Separation Model
    • 24-hour maternal separation impairs prepulse inhibition and latent inhibition, and increases stereotyped gnawing behavior.
  4. Electrical Stimulation Model
    • Electrodes implanted in the right VTA of 200–300g female Wistar rats.
    • Parameters: 1 ms pulse width, 100 Hz frequency, 2s duration, 10–100 μA stimulation 10 times, 5 min intervals.
    • Advantages: Simulates positive and negative symptoms, high stability, suitable for long-term use.

III. Transgenic Models

  1. COMT Knockout Model
    • COMT is a schizophrenia susceptibility gene.
    • Heterozygous deletion shows exploration and social deficits; homozygous knockout shows changes in spatial learning and working memory.
  2. NRG1 Knockout Model
    • NRG1 is a susceptibility gene; its receptor is ErbB4.
    • Knockout mice exhibit schizophrenia-like behavior, which can be improved by antipsychotic drugs.
  3. DISC1 Knockout Model
    • DISC1 is a susceptibility gene.
    • Transgenic mice show good spatial learning but impaired working memory and executive function. Suitable for mechanistic and therapeutic research.

IV. Multi-method Comprehensive Models

  1. Pharmacological + Neurodevelopmental: Repeated neonatal ketamine treatment combined with maternal separation.
  2. Pharmacological + Transgenic: C57BL/6 and GAD67-GFP mice combined with MK801. Long-term ≤1 mg/kg MK801 shows dose-related ataxia and stereotyped behavior.
  3. Neurodevelopmental + Transgenic: NRG1 knockout combined with chronic social stress; isolation rearing combined with PCP injection induces more severe cognitive impairment.

Key Detection Indicators

Behavioral Indicators:

  • Hallucination-like and delusion-like behaviors (model phenotype)
  • Stereotyped movements
  • Social behavior
  • Working memory
  • Spatial learning capacity
  • Prepulse inhibition (PPI) and latent inhibition (LI)

Neurobiological Indicators:

  • NMDA receptor function
  • White matter demyelination changes
  • Neurodevelopmental abnormalities
  • Susceptibility gene-related behavioral changes

相关产品